Recursion Pharmaceuticals and Schrodinger leverage their respective AI drug discovery platforms to potentially develop distinguished therapeutic candidates.

Clinical trials, traditionally plagued by low success rates and high operational costs, are being reengineered through AI ...

Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today issued the following statement regarding ...

GBAC “Quantum Healthcare 2025” board blueprint—$3.2 B QC drug-discovery market, 42 % CAGR, 50–70 % faster R&D cycles ...

Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today issued the following statement regarding its dispute with Renovaro, Inc.

BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced that six abstracts have been accepted at the 2025 ASCO Annual Meeting (ASCO), scheduled to take place ...

Learn about Capex trends, data center growth, and how to invest in the infrastructure powering generative AI. Discover how hyperscaler capex is driving the future of cloud computing and AI.

In a landmark announcement that bridges Asia and Europe, Leo International Group has acquired a controlling stake in SPOABG ...

AI researchers, clinicians and entrepreneurs explored the potential of AI for healthcare at a showcase Imperial Global USA event in San Francisco.An ...

Wipro Limited , a leading technology services and consulting company, today released its "State of Cybersecurity Report 2025." The report underscores the growing importance of integrating AI into ...

Simulations Plus, a trailblazer in biosimulation software and services, is transforming the pharmaceutical industry with ...

Deep Intelligent Pharma (DIP) has officially launched a groundbreaking generative AI platform that promises to redefine how ...